Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Macrovascular Complications of Type 2 Diabetes Mellitus

Author(s): Margus Viigimaa*, Alexandros Sachinidis, Maria Toumpourleka, Konstantinos Koutsampasopoulos, Signe Alliksoo and Tiina Titma

Volume 18, Issue 2, 2020

Page: [110 - 116] Pages: 7

DOI: 10.2174/1570161117666190405165151

Price: $65

Abstract

Background: Type 2 diabetes mellitus (T2DM) has emerged as a pandemic. It has different complications, both microvascular and macrovascular.

Objective: The purpose of this review is to summarize the different types of macrovascular complications associated with T2DM.

Methods: A comprehensive review of the literature was performed to identify clinical studies, which determine the macrovascular complications associated with T2DM.

Results: Macrovascular complications of T2DM include coronary heart disease, cardiomyopathy, arrhythmias and sudden death, cerebrovascular disease and peripheral artery disease. Cardiovascular disease is the primary cause of death in diabetic patients. Many clinical studies have shown a connection between T2DM and vascular disease, but almost always other risk factors are present in diabetic patients, such as hypertension, obesity and dyslipidaemia.

Conclusion: T2DM causes a variety of macrovascular complications through different pathogenetic pathways that include hyperglycaemia and insulin resistance. The association between T2DM and cardiovascular disease is clear, but we need more clinical studies in order to identify the pure effect of T2DM.

Keywords: Type 2 diabetes mellitus, macrovascular complications, coronary heart disease, cerebrovascular disease, hyperglycaemia, heart failure.

« Previous Next »
Graphical Abstract

[1]
Global report on diabetes. World Health Organization 2016.
[2]
Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008; 26: 2.
[3]
Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106: 171-6.
[4]
Kim JA, Montagnani M, Koh KK, et al. Reciprocal relationships between insulin resistance and endothelial dysfunction: Molecular and pathophysiological mechanisms. Circulation 2006; 113: 1888-904.
[5]
Du X, Edelstein D, Obici S, et al. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest 2006; 116: 1071-80.
[6]
Hasegawa Y, Saito T, Ogihara T, et al. Blockade of the nuclear factor-κB pathway in the endothelium prevents insulin resistance and prolongs life spans. Circulation 2012; 125: 1122-33.
[7]
Chaudhuri A, Janicke D, Wilson MF, et al. Anti-Inflammatory and profibrinolytic effect of insulin in acute ST-Segment- Elevation myocardial infarction. Circulation 2004; 109: 849-54.
[8]
Vinik AI, Erbas T, Sun Park T, et al. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1476-85.
[9]
Paneni F, Beckman JA, Creager MA, et al. Diabetes and vascular disease: Pathophysiology, clinical consequences and medical therapy: part I. Eur Heart J 2013; 34: 2436-43.
[10]
Geraldes P, King GL. Activation of protein kinase Cisoforms and its impact on diabetic complications. Circ Res 2010; 106: 1319-31.
[11]
Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49: 1939-45.
[12]
Du XL, Edelstein D, Dimmeler S, et al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 2001; 108: 1341-8.
[13]
Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107: 1058-70.
[14]
Boyle PJ. Diabetes mellitus and macro vascular disease: Mechanisms and mediators. Am J Med 2007; 120: S12-7.
[15]
Katakami N. Mechanism of Development of Atherosclerosis and Cardiovascular Disease in Diabetes Mellitus. J Atheroscler Thromb 2018; 25: 27-39.
[16]
Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: Epidemiology, pathophysiology and management. JAMA 2002; 287: 2570-81.
[17]
Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003; 46: 760-5.
[18]
Paterson AD, Rutledge BN, Cleary PA, et al. The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: The diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2007; 30: 2107-12.
[19]
Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003; 26: 917-32.
[20]
Kannel WB, McGee DL. Diabetes and cardiovascular disease: The framingham study. JAMA 1979; 241: 2035-8.
[21]
Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
[22]
Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 41: 2669-701.
[23]
Lehto S, Ronnemaa T, Pyorala K, et al. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke 1996; 27: 63-8.
[24]
Almdal T, Scharling H, Jensen JS, et al. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke and death: A population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004; 164: 1422-6.
[25]
Schramm TK, Gislason GH, Køber L, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: A population study of 3.3 million people. Circulation 2008; 117: 1945-54.
[26]
Bulugahapitiya U, Siyambalapitiya S, Sithole J, et al. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med 2009; 26: 142-8.
[27]
Jensen LO, Maeng M, Thayssen P, et al. Influence of diabetes mellitus on clinical outcomes following primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2012; 109: 629-35.
[28]
Machecourt J, Danchin N, Lablanche JM, et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients. The EVASTENT matched-cohort registry. J Am Coll Cardiol 2007; 50: 501-8.
[29]
Woods SE, Smith JM, Sohail S, et al. The influence of type 2 diabetes mellitus in patients undergoing coronary artery bypass graft surgery: An 8-year prospective cohort study. Chest 2004; 126: 1789-95.
[30]
Aneja A, Tang WH, Bansilal S, et al. Diabetic cardiomyopathy: Insights into pathogenesis, diagnostic challenges and therapeutic options. Am J Med 2008; 121: 748-57.
[31]
Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: Evidence, mechanisms and therapeutic implications. Endocr Rev 2004; 25: 543-67.
[32]
Seferović PM, Paulus WJ. Clinical diabetic cardiomyopathy: A two-faced disease with restrictive and dilated phenotypes. Eur Heart J 2015; 36: 1718-27.
[33]
Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30: 595-602.
[34]
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 321: 405-12.
[35]
Nichols GA, Gullion CM, Koro CE, et al. The incidence of congestive heart failure in type 2 diabetes: An update. Diabetes Care 2004; 27: 1879-84.
[36]
Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001; 103: 2668-73.
[37]
Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The framingham study. Am J Cardiol 1974; 34: 29-34.
[38]
Jaffe AS, Spadaro JJ, Schechtman K, et al. Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus. Am Heart J 1984; 108: 31-7.
[39]
Iwasaka T, Takahashi N, Nakamura S, et al. Residual left ventricular pump function after acute myocardial infarction in NIDDM patients. Diabetes Care 1992; 15: 1522-6.
[40]
Galderisi M, Anderson KM, Wilson PW, et al. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 1991; 68: 85-9.
[41]
Rutter MK, Parise H, Benjamin EJ, et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: Sex-related differences in the framingham heart study. Circulation 2003; 107: 448-54.
[42]
Eguchi K, Boden-Albala B, Jin Z, et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol 2008; 101: 1787-91.
[43]
Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function: The strong heart study. Circulation 2000; 101: 2271-6.
[44]
Zarich SW, Arbuckle BE, Cohen LR, et al. Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography. J Am Coll Cardiol 1988; 12: 114-20.
[45]
Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 2014; 57: 660-71.
[46]
Agarwal G, Singh SK. Arrhythmias in type 2 diabetes mellitus. Indian J Endocrinol Metab 2017; 21: 715-8.
[47]
Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 2005; 105: 315-8.
[48]
Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: Incidence, risk factors and prognosis in the Manitoba follow-up Study. Am J Med 1995; 98: 476-84.
[49]
Dublin S, Glazer NL, Smith NL, et al. Diabetes mellitus, glycemic control and risk of atrial fibrillation. J Gen Intern Med 2010; 25: 853-8.
[50]
Ruigomez A, Johansson S, Wallander MA, et al. Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol 2002; 55: 358-63.
[51]
Johansen OE, Brustad E, Enger S, et al. Prevalence of abnormal glucose metabolism in atrial fibrillation: A case control study in 75-year old subjects. Cardiovasc Diabetol 2008; 7: 28.
[52]
Schoen T, Pradhan AD, Albert CM, et al. Type 2 diabetes mellitus and risk of incident atrial fibrillation in women. J Am Coll Cardiol 2012; 60: 1421-8.
[53]
Ostgren CJ, Merlo J, Rastam L, et al. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes Obes Metab 2004; 6: 367-74.
[54]
Huxley RR, Filion KB, Konety S, et al. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 2011; 108: 56-62.
[55]
Vasiliadis I, Kolovou G, Mavrogeni S, et al. Sudden cardiac death and diabetes mellitus. J Diabetes Complications 2014; 28: 573-9.
[56]
Eranti A, Kerola T, Aro AL, et al. Diabetes, glucose tolerance and the risk of sudden cardiac death. BMC Cardiovasc Disord 2016; 16: 51.
[57]
Chen R, Ovbiagele B, Feng W. Diabetes and Stroke: Epidemiology, pathophysiology, pharmaceuticals and outcomes. Am J Med Sci 2016; 351: 380-6.
[58]
O’Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study. Lancet 2010; 376: 112-23.
[59]
Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-22.
[60]
Jia Q, Zhao X, Wang C, et al. Diabetes and poor outcomes within 6months after acute ischemic stroke: The China national stroke registry. Stroke 2011; 42: 2758-62.
[61]
Knoflach M, Matosevic B, Rucker M, et al. Functional recovery after ischemic stroke - matter of age: Data from the Austrian Stroke Unit Registry. Neurology 2012; 78: 279-85.
[62]
Osei E, Fonville S, Zandbergen AAM, et al. Glucose in prediabetic and diabetic range and outcome after stroke. Acta Neurologica Scandinavica 2017; 135: 170-5.
[63]
Lange S, Diehm C, Darius H, et al. High prevalence of peripheral arterial disease and low treatment rates in elderly primary care patients with diabetes. Experimental Clin Endocrinol Diabetes 2004; 112: 566-73.
[64]
Aquino R, Johnnides C, Makaroun M, et al. Natural history of claudication: Long-term serial follow-up study of 1244 claudicants. J Vasc Surg 2001; 34: 962-70.
[65]
Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-24.
[66]
Clairotte C, Retout S, Potier L, et al. Automated ankle-brachial pressure index measurement by clinical staff for peripheral arterial disease diagnosis in nondiabetic and diabetic patients. Diabetes Care 2009; 32: 1231-6.
[67]
Jude EB, Eleftheriadou I, Tentolouris N. Peripheral arterial disease in diabetes - A review. Dia Med 2010; 27: 4-14.
[68]
Yokoyama H, Sone H, Honjo J, et al. Relationship between a low ankle brachial index and all-cause death and cardiovascular events in subjects with and without diabetes. J Atheroscler Thromb 2014; 21: 574-81.

Rights & Permissions Print Cite
Article Metrics
186
28
1
© 2024 Bentham Science Publishers | Privacy Policy